Even in Denmark — Novo Nordisk's dwelling current market — an application for Wegovy to receive community wellness insurance coverage was rejected around the grounds that its cost was incommensurate with its therapeutic worth.Meantime, supply constraints could dampen initial distribution in a marketplace forecast to be truly worth $200 billion